Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study This open-label, randomized, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback